BioRestorative Therapies, Inc. (BRTX) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 3 Buy.
Analysts estimate Earnings Per Share (EPS) of $-1.41 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.16 vs est $-1.41 (beat +17.5%). 2025: actual $-1.58 vs est $-1.63 (beat +3.1%). Analyst accuracy: 88%.
BRTX Analyst Ratings
Buy
Based on 3 analysts giving stock ratings to BioRestorative Therapies, Inc. in the past 3 months
EPS Estimates — BRTX
88%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.16
vs Est –$1.41
▲ 21.3% off
2025
Actual –$1.58
vs Est –$1.63
▲ 3.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — BRTX
25%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.001B
▼ 113.3% off
2025
Actual $0.000B
vs Est $0.000B
▼ 36.2% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
